FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptidePRNewsWire • 03/18/26
Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru LaunchBusiness Wire • 03/16/26
Eve-of-Trial $65M Settlement Preliminarily Approved in Novel Antitrust Class Action Against J&J Subsidiary Actelion PharmaceuticalsGlobeNewsWire • 03/13/26
Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancerPRNewsWire • 03/13/26
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract PatientsBusiness Wire • 03/12/26
The Zacks Analyst Blog JPMorgan, Johnson & Johnson, Applied Materials and Value LineZacks Investment Research • 03/12/26
JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EUZacks Investment Research • 03/11/26
Hope for the Best and Plan for the Worst: The 5 Safest Dividend Aristocrats24/7 Wall Street • 03/11/26
Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/10/26
These 7 Elite Dividend Stocks Pay $114 Billion Annually, Combined, to Their ShareholdersThe Motley Fool • 03/08/26
Dividend Aristocrats in a Shaky Market: KO, PG, JNJ, and 2 Others Built to Last24/7 Wall Street • 03/06/26